These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28695544)

  • 1. Performance-Based Risk-Sharing Arrangements: An Updated International Review.
    Carlson JJ; Chen S; Garrison LP
    Pharmacoeconomics; 2017 Oct; 35(10):1063-1072. PubMed ID: 28695544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.
    Carlson JJ; Gries KS; Yeung K; Sullivan SD; Garrison LP
    Appl Health Econ Health Policy; 2014 Jun; 12(3):231-8. PubMed ID: 24664994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review.
    Chen Y; Carlson JJ
    J Manag Care Spec Pharm; 2022 Jan; 28(1):78-83. PubMed ID: 34949115
    [No Abstract]   [Full Text] [Related]  

  • 5. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review.
    Yu JS; Chin L; Oh J; Farias J
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1028-1040. PubMed ID: 28944733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
    Kim AE; Choi DH; Chang J; Kim SH
    Clin Drug Investig; 2020 Dec; 40(12):1107-1113. PubMed ID: 33037566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market.
    Xu W; Wu J
    Int J Technol Assess Health Care; 2020 Oct; 36(5):486-491. PubMed ID: 32962784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
    Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging roles for pharmacists in performance-based risk-sharing arrangements.
    Calabrese MJ; Cooke CE; Watson K; de Bittner MR
    Am J Health Syst Pharm; 2017 Jul; 74(13):1007-1012. PubMed ID: 28522641
    [No Abstract]   [Full Text] [Related]  

  • 10. When do performance-based risk-sharing arrangements make sense?
    Drummond M
    Eur J Health Econ; 2015 Jul; 16(6):569-71. PubMed ID: 25783211
    [No Abstract]   [Full Text] [Related]  

  • 11. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicians, hospitals and health plans seek new risk-sharing arrangements.
    Capitation Manag Rep; 2005 Oct; 12(10):116-20, 109. PubMed ID: 16305048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient access schemes in Asia-pacific markets: current experience and future potential.
    Lu CY; Lupton C; Rakowsky S; Babar ZU; Ross-Degnan D; Wagner AK
    J Pharm Policy Pract; 2015; 8(1):6. PubMed ID: 25815200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
    Hammerman A; Feder-Bubis P; Greenberg D
    Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers".
    Curto A; Garattini L
    Appl Health Econ Health Policy; 2014 Oct; 12(5):565. PubMed ID: 25124262
    [No Abstract]   [Full Text] [Related]  

  • 16. Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.
    Strohbehn GW; Cooperrider JH; Yang D; Fendrick AM; Ratain MJ; Zaric GS
    Value Health Reg Issues; 2022 Sep; 31():34-38. PubMed ID: 35395499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk sharing schemes--what does foreign experience tell us?].
    Kolasa K
    Pol Merkur Lekarski; 2013 Oct; 35(208):214-6. PubMed ID: 24340892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Authors' reply to Curto and Garattini: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers".
    Carlson JJ; Gries K; Yeung K; Sullivan SD; Garrison LP
    Appl Health Econ Health Policy; 2014 Oct; 12(5):567-8. PubMed ID: 25124263
    [No Abstract]   [Full Text] [Related]  

  • 19. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.